XML 53 R43.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($) $ in Millions |  | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Mar. 11, 2022 | Oct. 02, 2022 | Apr. 03, 2022 | Oct. 03, 2021 | Oct. 02, 2022 | Oct. 03, 2021
Restructuring charges/(credits): |  |  |  |  |  |  |
Employee terminations |  |  | $ 158 |  | $ 630 | $ 293 | $ 649
Asset impairments |  |  | 17 |  | 10 | 44 | 7
Exit costs/(credits) |  |  | 2 |  | 3 | 31 | 0
Restructuring charges/(credits) | [1] |  | 177 |  | 643 | 368 | 656
Transaction costs | [2] |  | 0 |  | 0 | 42 | 0
Integration costs and other | [3] |  | 22 |  | 3 | 170 | 11
Restructuring charges and certain acquisition-related costs |  |  | 199 |  | 646 | 580 | 667
Additional depreciation––asset restructuring | [4] |  | 7 |  | 27 | 22 | 76
Implementation costs | [5] |  | 150 |  | 151 | 384 | 316
Total costs associated with acquisitions and cost-reduction/productivity initiatives |  |  | 357 |  | 760 | 982 | 1,008
Biopharma [Member] |  |  |  |  |  |  |
Restructuring charges/(credits): |  |  |  |  |  |  |
Restructuring charges/(credits) |  |  | 62 |  | 616 | 108 | 617
Other (income)/deductions––net [Member] |  |  |  |  |  |  |
Restructuring charges/(credits): |  |  |  |  |  |  |
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net |  |  | 0 |  | (63) | (5) | (51)
Cost of sales [Member] |  |  |  |  |  |  |
Restructuring charges/(credits): |  |  |  |  |  |  |
Additional depreciation––asset restructuring | [4] |  | 7 |  | 19 | 22 | 53
Implementation costs | [5] |  | 14 |  | 8 | 40 | 29
Selling, informational and administrative expenses [Member] |  |  |  |  |  |  |
Restructuring charges/(credits): |  |  |  |  |  |  |
Additional depreciation––asset restructuring | [4] |  | 1 |  | 8 | 1 | 23
Implementation costs | [5] |  | 136 |  | 142 | 344 | 287
Research and Development Expense [Member] |  |  |  |  |  |  |
Restructuring charges/(credits): |  |  |  |  |  |  |
Implementation costs | [5] |  | $ 0 |  | $ 0 | $ 0 | $ 1
Restructuring Charges And Acquisition-Related Costs [Member] | Arena [Member] |  |  |  |  |  |  |
Restructuring charges/(credits): |  |  |  |  |  |  |
Post closing compensation expense |  | $ 138 |  | $ 138 |  |  |
[1] | Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $62 million and $108 million for the three and nine months ended October 2, 2022, respectively, and charges of $616 million and $617 million for the three and nine months ended October 3, 2021, respectively.
[2] | Represents external costs for banking, legal, accounting and other similar services.
[3] | Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the three and nine months ended October 2, 2022, integration costs and other were mostly related to our acquisition of Arena, including $138 million in payments to Arena employees in the first quarter of 2022 for the fair value of previously unvested long-term incentive awards. See Note 2A.
[4] | Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[5] | Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

X
- Definition This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services. + References No definition available. + Details
Name: | pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services. + References No definition available. + Details
Name: | pfe_ImplementationCosts
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Restructuring, Asset Impairment Charges + References No definition available. + Details
Name: | pfe_RestructuringAssetImpairmentCharges
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Restructuring Charges, Acquisition Related Costs and Implementation Costs + References No definition available. + Details
Name: | pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities. + References No definition available. + Details
Name: | pfe_RestructuringChargesAndAcquisitionRelatedCosts
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs. + References No definition available. + Details
Name: | us-gaap_BusinessCombinationIntegrationRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(3) -URI https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 + Details
Name: | us-gaap_BusinessExitCosts1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of net periodic benefit cost (credit) for defined benefit plan. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 6 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 55 -Paragraph 17 -URI https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 55 -Paragraph 18 -URI https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (h) -URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920 + Details
Name: | us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 45 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -URI https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(1)) -URI https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_RestructuringCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RestructuringChargesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan. + References No definition available. + Details
Name: | us-gaap_RestructuringReserveAcceleratedDepreciation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 + Details
Name: | us-gaap_SeveranceCosts1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=pfe_ArenaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |